〔Abstract〕 Objective To observe the effects of asunprevir (ASV) combined with daclatasvir (DCV) on hepatic and renal function in elderly patients with compensated hepatitis C (CHC) cirrhosis. Methods A total of 76 elderly patients with CHC cirrhosis admitted to Shangqiu Municipal Hospital were enrolled as the research objects from March 2018 to April 2020, and they were randomly divided into an observation group and a control group, with 38 cases in each group. The observation group was treated with ASV combined with DCV, while control group was treated with low-dose interferon and ribavirin. After 12 weeks of treatment, the hepatitis C virus (HCV) ribonucleic acid (RNA) negative conversion rate and virological response rate were compared between the two groups. The hepatic and renal function and fibrosis indexes were compared between the two groups before and after treatment. The incidence of adverse reactions was compared between the two groups during treatment. Results After 12 weeks of treatment, the HCV-RNA negative conversion rate and virological response rate at each stage in the observation group were higher than those in the control group, the differences were statistically significant (P < 0.05). At 12 and 24 weeks of treatment, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), hyaluronase, laminin (LN), type III procollagen (PC-III) and type Ⅳ collagen (C-Ⅳ) in the two groups were lower than those before treatment, and after 24 weeks of treatment, the observation group was lower than that in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P > 0.05). Conclusion ASV combined with DCV is effective in the treatment of elderly patients with CHC cirrhosis, and does not cause further damage to hepatic and renal function.